X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

By Nicole Longo  |    November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...   Read More

Study finds middlemen excluded nearly 850 medicines from formularies this year

By Katie Koziara  |    September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...   Read More

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

By Holly Campbell  |    March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt  patients’ ability...   Read More

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

Five key facts about the market for insulins

By Holly Campbell  |    April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...   Read More

The PBM story you haven’t heard: Hidden fees quadrupled in two years

By Robert Zirkelbach  |    March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...   Read More

OptumRX: Sharing rebates with patients is “worth it”

By Holly Campbell  |    March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...   Read More

Event tomorrow: Making the biopharmaceutical supply chain work for patients

By Katie Koziara  |    May 2, 2018
In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...   Read More

Advance price notification: A transparency measure that fails patients

By Saumil Pandya and Emily Donaldson  |    March 29, 2018
Most transparency reforms aim to correct perceived misaligned incentives in the biopharmaceutical marketplace. However, many efforts to mandate information flow in the private market have serious...   Read More

New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed

By Holly Campbell  |    March 27, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates